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Abstract
Purpose of review—Elevated plasma triglyceride and reduced HDL concentrations are
prominent features of metabolic syndrome and type 2 diabetes. Individuals with Tangier disease
also have elevated plasma triglyceride concentrations and very low HDL, resulting from mutations
in ATP-binding cassette transporter A1 (ABCA1), an integral membrane protein that facilitates
nascent HDL particle assembly. Past studies attributed the inverse relationship between plasma
HDL and triglyceride to intravascular lipid exchange and catabolic events. However, recent
studies also suggest that hepatic signaling and lipid mobilization and secretion may explain how
HDL affects plasma triglyceride concentrations.
Recent findings—Hepatocyte-specific ABCA1 knockout mice have markedly reduced plasma
HDL and a two-fold increase in triglyceride due to failure to assemble nascent HDL particles by
hepatocytes, causing increased catabolism of HDL apolipoprotein A-I and increased hepatic
production of triglyceride-enriched VLDL. In-vitro studies suggest that nascent HDL particles
may induce signaling to decrease triglyceride secretion. Inhibition of microRNA 33 expression in
nonhuman primates augments hepatic ABCA1, genes involved in fatty acid oxidation, and
decreases expression of lipogenic genes, causing increased plasma HDL and decreased
triglyceride levels.
Summary—New evidence suggests potential mechanisms by which hepatic ABCA1-mediated
nascent HDL formation regulates VLDL–triglyceride production and contributes to the inverse
relationship between plasma HDL and triglyceride.
Keywords
ATP-binding cassette transporter A1; high-density lipoprotein formation; mRNA; Tangier disease;
very low-density lipoprotein production
INTRODUCTION
ATP-binding cassette (ABC) transporters constitute a large family of integral membrane
proteins that transport a variety of small molecules across cell membranes. ATP-binding
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cassette transporter A1 (ABCA1) is a member of the ABC transporter family that is required
for the formation of plasma HDL. Mutations in ABCA1 cause Tangier disease, an autosomal
recessive disorder characterized by severe HDL deficiency, sterol deposition in tissues, and
premature coronary atherosclerosis [1]. In addition to HDL deficiency, Tangier disease
patients have significantly elevated plasma triglyceride concentrations [1–3]. An inverse
relationship between dysfunctional ABCA1 alleles and plasma triglyceride concentrations
has been reported [2], but the underlying mechanisms for the increased plasma triglyceride
concentrations in Tangier disease patients have not been established. Metabolic syndrome
and type 2 diabetes are also characterized by elevated VLDL triglyceride and reduced HDL
concentrations [4,5], a plasma lipoprotein phenotype similar to Tangier disease.
One explanation for the inverse association between plasma HDL and triglyceride involves
intravascular metabolism. Elevated plasma VLDL–triglyceride levels in type 2 diabetes
appear due to enhanced hepatic production of large, triglyceride-enriched VLDL particles,
referred to as VLDL1 [6,7]. Intravascular exchange of excess VLDL–triglyceride and HDL
cholesteryl ester, mediated by cholesteryl ester transfer protein, leads to HDL-triglyceride
enrichment, followed by lipolysis of HDL–triglyceride. This creates smaller HDL particles
that are more rapidly removed from the circulation [8]. Hydrolysis of VLDL or HDL–
triglyceride also generates redundant phospholipid surface that can serve as substrate for
plasma HDL production [9]. Over the past several years, however, new information has
emerged implicating a key role for the liver in regulating the reciprocal relationship between
plasma triglyceride and HDL. This review will summarize recently published studies on the
regulation of plasma triglyceride and HDL by ABCA1 and miR-33 expression.
HEPATIC ATP-BINDING CASSETTE TRANSPORTER A1 AND
TRIGLYCERIDE METABOLISM: IN-VITRO STUDIES
Sahoo et al. [10] previously reported that hepatocyte ABCA1-dependent cholesterol efflux
decreased VLDL secretion, presumably by limiting cholesterol availability for VLDL
particle assembly. These findings provided the first potential mechanistic link between
hepatic ABCA1 and VLDL secretion. Recent in-vitro studies using oleic acid-stimulated
McArdle RH7777 (McA) rat hepatoma cells have provided new insights into the
relationship between hepatic ABCA1 expression and triglyceride secretion [11▪]. Silencing
of ABCA1 in McA cells with siRNA reduced ABCA1 protein expression by more than 70%
and increased triglyceride secretion two-fold compared with control siRNA-treated cells
[11▪], whereas apoB protein secretion was only modestly increased (~15%). In addition, the
ABCA1- silenced McA cells secreted larger (1.6-fold) VLDL particles that floated in the
VLDL1 fraction. The increased VLDL–triglyceride secretion from ABCA1-silenced McA
cells was not due to changes in expression of microsomal transfer protein or signaling
through mammalian target of rapamycin or mitogen-activated protein kinase/extracellular
signal-regulated kinase pathways. However, phosphoinositide 3 (PI3) kinase activation was
diminished with ABCA1 silencing, and chemical inhibition of PI3 kinase increased
triglyceride secretion in control siRNA transfected McA cells to levels observed for
ABCA1-silenced McA cells. These results suggested that ABCA1 expression affected
triglyceride mobilization for the second step of VLDL particle maturation, a process that
was previously shown to be impacted by insulin and PI3 kinase signaling [12,13]. Because
ABCA1 has no known direct role in triglyceride transport, the authors hypothesized that
silencing of ABCA1 reduced nascent HDL production, which in turn, resulted in increased
triglyceride secretion. To explore this hypothesis, oleic acid-stimulated McA cells were
incubated with apolipoprotein A-I (apoA-I), resulting in assembly of heterogeneous-sized
(7–16 nm diameter) nascent HDL particles, similar to those reported for ABCA1-transfected
HEK293 cells [14]. When nascent HDL-containing conditioned medium from either McA
rat hepatoma cells or HEK293 cells transfected with ABCA1 were incubated with ABCA1-
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silenced McA cells, both were effective in increasing PI3 kinase activation and reducing
VLDL–triglyceride secretion, whereas nonconditioned medium lacking nascent HDL was
not. Addition of isolated large (>10 nm diameter) nascent HDL particles to ABCA1-silenced
McA hepatoma cells inhibited VLDL–triglyceride secretion to a greater extent than small
(<10 nm diameter) nascent HDL. Similarly, addition of recombinant HDL made in vitro
with synthetic lipids and apoA-I, but not human plasma HDL, was effective in attenuating
triglyceride secretion and increasing PI3 kinase activation in ABCA1-silenced McA cells.
Collectively, these data suggest that large nascent HDL particles, assembled by ABCA1 but
not mature plasma HDL, generate a PI3 kinase-mediated autocrine/paracrine signal that
attenuates VLDL maturation and triglyceride secretion. These results provided a novel
potential mechanistic link between nascent HDL particle formation by hepatic ABCA1 and
VLDL–triglyceride secretion.
HEPATIC ATP-BINDING CASSETTE TRANSPORTER A1 AND
TRIGLYCERIDE METABOLISM: IN-VIVO STUDIES
Because ABCA1 is expressed in many tissues to varying degrees [15], in-vivo evidence for
its role in hepatic triglyceride metabolism was lacking until hepatocyte-specific ABCA1
knockout (HSKO) mice were generated [16]. Relative to wild-type controls, HSKO mice
have reduced plasma HDL (20% of wild type) and LDL (50% of wild type) and a two-fold
increase in plasma triglyceride concentrations [17▪▪]. The reduction in plasma HDL resulted
from failure of hepatocytes to efflux free cholesterol and phospholipid to form nascent HDL
particles, leading to increased kidney catabolism of apoA-I [16,18▪]. The reduction in
plasma LDL concentrations in HSKO mice was due to increased hepatic LDL receptor
expression, which caused greater hepatic removal of LDL from the circulation. Genetic
deletion of LDL receptors in HSKO mice raised plasma LDL concentrations to levels
comparable to LDL receptor knockout mice, providing additional mechanistic support for
the idea that increased LDL receptor expression in HSKO mice causes reduced plasma LDL
concentrations. The increased plasma triglyceride observed in HSKO mice was attributed to
a two-fold increase in hepatic triglyceride production in vivo and in isolated hepatocytes, in
vitro [17▪▪]. The augmented hepatic triglyceride production was due to greater secretion of
large VLDL1 particles, with no significant alteration in hepatic lipid content or microsomal
triglyceride transfer protein expression [17▪▪]. Furthermore, hepatic PI3 kinase activation
was attenuated in HSKO mice compared with wild-type mice after acute insulin injection or
in response to fasting and refeeding. Acute pharmacological inhibition of PI3 kinase with
wortmannin, in vivo, resulted in increased hepatic triglyceride secretion in wild-type mice,
similar to that observed in HSKO mice without PI3 kinase inhibition. These data are
remarkably similar to those obtained with silencing of ABCA1 in McA cells and support an
essential role for hepatic ABCA1 in regulating VLDL triglyceride secretion.
An additional mechanism for the elevated plasma triglyceride concentrations in HSKO mice
was decreased postheparin hepatic lipase and lipoprotein lipase activity compared with wild-
type mice [17▪▪]. This finding was further supported by delayed in-vivo clearance of
postprandial triglyceride after an oral fat load. The molecular explanation for this decreased
lipolytic activity is unknown; however, these observations in HSKO mice agree with similar
data demonstrating decreased lipoprotein lipase activity [19] and delayed clearance of
postprandial lipid in Tangier disease patients [3].
Because the plasma lipid phenotype in Tangier disease is similar to that in HSKO mice, it
appears that much of the Tangier disease lipid phenotype is due to ABCA1 deficiency in
hepatocytes. In addition, studies in HSKO mice suggest that two distinct mechanisms are
responsible for the elevated plasma triglyceride concentrations and reduced LDL levels in
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ABCA1-deficient states: hepatic overproduction of triglyceride and reduced triglyceride
lipolysis for the former, and increased hepatic LDL receptor expression for the latter.
In another recent study, adenovirus-mediated overexpression of murine ABCA1 in male
apoE knockout mice resulted in a two-fold increase in liver ABCA1 protein expression and
increased plasma LDL and HDL concentrations, a phenotype that, as expected, is opposite
of that observed in HSKO mice and which caused enhanced atherosclerosis [20]. A
quantitatively greater increase in LDL compared with HDL, along with formation of
dysfunctional HDL under conditions of ABCA1 excess, may partially explain the increased
atherosclerosis in mice overexpressing ABCA1 [20]. Interestingly, however, plasma
triglyceride levels were unchanged in these animals, in agreement with some [21–23], but
not all [24], previous ABCA1 overexpression (transgenic or adenovirus) studies. The
absence of a triglyceride phenotype upon ABCA1 overexpression suggests that normal
levels of ABCA1-generated nascent HDL may be sufficient to fully attenuate hepatic
triglyceride secretion, with no further impact upon ABCA1 overexpression.
REGULATION OF ATP-BINDING CASSETTE TRANSPORTER A1 AND
TRIGLYCERIDE BY MICRORNA-33
microRNAs are small noncoding RNA molecules that are important post-transcriptional
regulators of gene expression [25▪]. Two microRNAs (miR-33a and miR-33b) are known to
be important in regulating HDL concentrations. miR-33a and 33b are encoded within introns
of sterol regulatory element-binding protein (SREBP) 2 and SREBP1, respectively. SREBP1
and 2 are master transcription factors that control pathways of lipogenesis and sterol
biogenesis, respectively [26]. miR-33a is highly conserved throughout evolution, whereas
miR-33b is only expressed in nonrodent mammals. Once transcribed miR-33s are processed,
they bind to the 3′ untranslated region of mRNA-encoding genes involved in cellular
cholesterol export (i.e., ABCA1, ABCG1, NPC1) and fatty acid oxidation (CPT1, CROT,
HADHB), repressing their expression. Antagonism of miR-33 with anti-miR-33
oligonucleotides increased hepatic ABCA1 expression and plasma HDL concentrations, and
decreased atherosclerosis in atherogenic diet-fed LDL receptor knockout mice, compared
with mice treated with control anti-miR; however, plasma triglyceride concentrations were
unaltered [27▪▪]. An explanation for this apparent discrepancy is that miR-33b is not
expressed in mice, so potential anti-miR-33 effects that might accompany SREBP1-
mediated lipogenesis and hepatic triglyceride production would be absent. Recently,
inhibition of miR-33a/b was reported in African green monkeys, a species that, like humans,
expresses miR-33b [28▪▪]. miR-33a/b inhibition resulted in increased expression of hepatic
ABCA1 protein and increased plasma HDL concentrations [28▪▪], similar to previous results
in mice [27▪▪]. In addition, miR-33a/b inhibition in monkeys increased expression of genes
involved in fatty acid oxidation and reduced expression of genes involved in hepatic
lipogenesis, resulting in marked reduction in plasma VLDL–triglyceride. Interestingly,
hepatic expression of SREBP1 mRNA and protein was reduced in monkeys treated with
anti-miR-33a/b, but the reasons for this response are not clear. These results represent
another example of coordinated hepatic regulation of HDL production and triglyceride
secretion that helps explain the reciprocal relationship between plasma HDL and triglyceride
in nonhuman primates and humans.
GENETIC VARIATION IN ATP-BINDING CASSETTE TRANSPORTER A1 AND
PLASMA TRIGLYCERIDE CONCENTRATIONS
Previous genome-wide association studies have reported a significant association between
single nucleotide polymorphisms in ABCA1 and plasma HDL concentrations [29]. On the
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contrary, genetic associations between ABCA1 and plasma triglyceride concentrations were
not apparent [30▪] until a recent study in a Chinese population found variants in ABCA1 that
were associated with plasma triglyceride and HDL [31]. Another study reported that
ABCA1 gene variants are associated with postprandial lipoprotein clearance from plasma of
healthy men [32▪]. The lack of consistent association between sequence variants of ABCA1
and plasma triglyceride concentrations may due to the inherent variability in triglyceride
levels in individuals in various states of postprandial dietary lipid absorption. In Tangier
disease patients who lack functional ABCA1, plasma triglyceride concentrations average
two-fold higher than in controls; however, even in individuals lacking ABCA1, plasma
triglyceride concentrations are quite variable [1].
CONCLUSION
Elevated plasma triglyceride and reduced HDL concentrations are prominent features of
metabolic syndrome and type 2 diabetes. The mechanism behind the reciprocal relationship
of these two lipid/lipoprotein components is poorly understood. Recent studies suggest two
independent mechanisms that involve hepatic ABCA1 expression. First, lack of hepatic
ABCA1 expression results in increased liver secretion of VLDL–triglyceride in a process
that involves PI3 kinase activation. Second, inhibition of hepatic miR-33 expression in
nonhuman primates increases expression of cholesterol export and fatty acid oxidation
genes, reducing plasma triglyceride and elevating HDL. These findings not only establish a
mechanistic link between plasma HDL and triglyceride but offer new potential therapeutic
avenues for individuals with metabolic syndrome and type 2 diabetes. In these individuals,
insulin resistance drives hyperinsulinemia, which in turn stimulates hepatic lipogenesis
through increased SREBP1 expression [33]. Coincident with increased SREBP1
transcription, increased miR-33b will diminish HDL production and increase triglyceride
secretion. Antagonism of miR-33 offers hope for reversing this phenotype, resulting in
increased HDL and reduced triglyceride concentrations.
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KEY POINTS
• Hepatic ABCA1 expression regulates VLDL triglyceride production through a
PI3 kinase-signaling step that involves nascent HDL.
• The similarity in plasma lipid phenotype between Tangier disease patients and
hepatocyte-specific ABCA1 knockout mice supports a major role for hepatic
ABCA1 expression in the regulation of plasma VLDL, LDL, and HDL
concentrations.
• Hepatic microRNA (miR) 33 expression results in reciprocal regulation of
plasma HDL and triglyceride concentrations in nonhuman primates.
• Silencing of miR-33 may be a new therapeutic option for raising plasma HDL
and lowering triglyceride levels in individuals with metabolic syndrome.
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